MHLW (Japan) approves Enhertu for the treatment of adult patients with HER2-low unresectable or recurrent breast cancer after prior chemotherapy.- Daiichi Sankyo
Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of adult patients with HER2-low unresectable or recurrent breast cancer after prior chemotherapy.The indication is for patients with HER2-low disease defined as immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization.
The regulatory decision was supported by data from the phase III DESTINY-Breast04 trial (NCT03734029), which showed that the antibody-drug conjugate (ADC) reduced the risk of progression or death by 50% compared with physician’s choice of chemotherapy in patients with hormone receptor–positive or –negative, HER2-low metastatic breast
Patients treated with trastuzumab deruxtecan experienced a median progression-free survival (PFS) of 9.9 months (95% CI, 9.0-11.3) compared with 5.1 months (95% CI, 4.2-6.8) for those given chemotherapy. Additionally, the ADC reduced the risk of death by 36% compared with chemotherapy (HR, 0.64; 95% CI, 0.49-0.84; P = .001).
Related news and insights
Acadia Pharmaceuticals announced that Nature Medicine published results from the pivotal Phase III LAVENDER trial, a 12-week randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Daybue (trofinetide) in patients with Rett syndrome five to 20 years of age
FibroGen, Inc.announced topline data from the Phase III LELANTOS-1 placebo-controlled trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne Muscular Dystrophy (DMD) on background corticosteroids
Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced that the FDA has approved Vevye (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease